Nasopharyngitis (Common Cold) - Pipeline Review, H2 2016

Date: July 20, 2016
Pages: 45
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: N7E94A3DFA5EN
Leaflet:

Download PDF Leaflet

Nasopharyngitis (Common Cold) - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Nasopharyngitis (Common Cold) - Pipeline Review, H2 2016’, provides an overview of the Nasopharyngitis (Common Cold) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nasopharyngitis (Common Cold), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nasopharyngitis (Common Cold) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Nasopharyngitis (Common Cold)
  • The report reviews pipeline therapeutics for Nasopharyngitis (Common Cold) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Nasopharyngitis (Common Cold) therapeutics and enlists all their major and minor projects
  • The report assesses Nasopharyngitis (Common Cold) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Nasopharyngitis (Common Cold)
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Nasopharyngitis (Common Cold)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Nasopharyngitis (Common Cold) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Nasopharyngitis (Common Cold) Overview
Therapeutics Development
Pipeline Products for Nasopharyngitis (Common Cold) - Overview
Pipeline Products for Nasopharyngitis (Common Cold) - Comparative Analysis
Nasopharyngitis (Common Cold) - Therapeutics under Development by Companies
Nasopharyngitis (Common Cold) - Therapeutics under Investigation by Universities/Institutes
Nasopharyngitis (Common Cold) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Nasopharyngitis (Common Cold) - Products under Development by Companies
Nasopharyngitis (Common Cold) - Products under Investigation by Universities/Institutes
Nasopharyngitis (Common Cold) - Companies Involved in Therapeutics Development
Charleston Laboratories, Inc.
Cocrystal Pharma, Inc.
Orbis Biosciences Inc
Vernalis Plc
Nasopharyngitis (Common Cold) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(levocetirizine dihydrochloride + montelukast sodium) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibodies to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCP-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCP-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCP-07 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCP-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLAT-313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
guaifenesin ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit MAPK13 for Asthma and Cold - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Common Cold - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nasopharyngitis (Common Cold) - Dormant Projects
Nasopharyngitis (Common Cold) - Discontinued Products
Nasopharyngitis (Common Cold) - Product Development Milestones
Featured News & Press Releases
Jul 08, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Comparative Bioavailability Study
Apr 14, 2016: Vernalis Announces Successful Completion of CCP-07 Pivotal Multiple-Dose Comparative Bioavailability Study
Dec 21, 2015: Vernalis Announces Successful Completion of CCP-07 Pivotal Single-Dose Comparative Bioavailability Study
Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine
Jun 11, 2015: Vernalis announces CCP-07 starts 12 month stability testing
Jul 22, 2014: Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Nasopharyngitis (Common Cold), H2 2016
Number of Products under Development for Nasopharyngitis (Common Cold) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Nasopharyngitis (Common Cold) - Pipeline by Charleston Laboratories, Inc., H2 2016
Nasopharyngitis (Common Cold) - Pipeline by Cocrystal Pharma, Inc., H2 2016
Nasopharyngitis (Common Cold) - Pipeline by Orbis Biosciences Inc, H2 2016
Nasopharyngitis (Common Cold) - Pipeline by Vernalis Plc, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Nasopharyngitis (Common Cold) - Dormant Projects, H2 2016
Nasopharyngitis (Common Cold) - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Nasopharyngitis (Common Cold), H2 2016
Number of Products under Development for Nasopharyngitis (Common Cold) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Charleston Laboratories, Inc.
Cocrystal Pharma, Inc.
Orbis Biosciences Inc
Vernalis Plc
Skip to top


Ask Your Question

Nasopharyngitis (Common Cold) - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: